Literature DB >> 29440240

Atypical presentation of atypical haemolytic uraemic syndrome.

Ratna Basak1, Xiaotong Wang2, Caitlin Keane1, Robert Woroniecki1.   

Abstract

A 17-year-old girl presented with fever, myalgia, vomiting for 1 month and oliguria and dyspnoea for 4 days. She was tachycardic,hypertensive, with pedal oedema and decreased breath sounds. She had high serum creatinine (3 mg/dL), anaemia, thrombocytopenia, leucocytosis and eosinophilia with schistocytes. Lactate dehydrogenase, transaminases were high , with low haptoglobin and high ferritin (5269 ng/mL). Complement C3/C4 and fibrinogen were normal. Urinalysis showed large blood and protein and stool studies were negative. Her ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) was normal. Kidney biopsy showed acute interstitial nephritis (AIN) in addition to thrombotic angiopathy. The differentials - haemolytic uraemic syndrome (HUS), thrombotic thrombocytopenia (TTP) and haemophagocytic lymphohistiocytosis (HLH) were ruled out. Her genetic testing was abnormal for large CFHR1-CFHR3 homozygous deletion and heterozygous missense variant in exon 2 of DGKE making the diagnosis of atypical HUS. She received eculizumab and was discharged on oral steroids for AIN and biweekly eculizumab infusions with excellent recovery. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  acute renal failure; medical management; paediatrics; renal medicine

Mesh:

Substances:

Year:  2018        PMID: 29440240      PMCID: PMC5836659          DOI: 10.1136/bcr-2017-222560

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

2.  The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study.

Authors:  Anne M Durkan; Siah Kim; Jonathan Craig; Elizabeth Elliott
Journal:  Arch Dis Child       Date:  2016-01-04       Impact factor: 3.791

Review 3.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

4.  Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Larry A Greenbaum; Marc Fila; Gianluigi Ardissino; Samhar I Al-Akash; Jonathan Evans; Paul Henning; Kenneth V Lieberman; Silvio Maringhini; Lars Pape; Lesley Rees; Nicole C A J van de Kar; Johan Vande Walle; Masayo Ogawa; Camille L Bedrosian; Christoph Licht
Journal:  Kidney Int       Date:  2016-01-28       Impact factor: 10.612

5.  Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome.

Authors:  Caterina Mele; Mathieu Lemaire; Paraskevas Iatropoulos; Rossella Piras; Elena Bresin; Serena Bettoni; David Bick; Daniel Helbling; Regan Veith; Elisabetta Valoti; Roberta Donadelli; Luisa Murer; Maria Neunhäuserer; Matteo Breno; Véronique Frémeaux-Bacchi; Richard Lifton; Giuseppe Remuzzi; Marina Noris
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.614

6.  The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε.

Authors:  Karolis Azukaitis; Eva Simkova; Mohammad Abdul Majid; Matthias Galiano; Kerstin Benz; Kerstin Amann; Clemens Bockmeyer; Radha Gajjar; Kevin E Meyers; Hae Il Cheong; Bärbel Lange-Sperandio; Therese Jungraithmayr; Véronique Frémeaux-Bacchi; Carsten Bergmann; Csaba Bereczki; Monika Miklaszewska; Dorottya Csuka; Zoltán Prohászka; Paul Killen; Patrick Gipson; Matthew G Sampson; Mathieu Lemaire; Franz Schaefer
Journal:  J Am Soc Nephrol       Date:  2017-05-19       Impact factor: 14.978

7.  DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN.

Authors:  Fatih Ozaltin; Binghua Li; Alysha Rauhauser; Sung-Wan An; Oguz Soylemezoglu; Ipek Isik Gonul; Ekim Z Taskiran; Tulin Ibsirlioglu; Emine Korkmaz; Yelda Bilginer; Ali Duzova; Seza Ozen; Rezan Topaloglu; Nesrin Besbas; Shazia Ashraf; Yong Du; Chaoying Liang; Phylip Chen; Dongmei Lu; Komal Vadnagara; Susan Arbuckle; Deborah Lewis; Benjamin Wakeland; Richard J Quigg; Richard F Ransom; Edward K Wakeland; Matthew K Topham; Nicolas G Bazan; Chandra Mohan; Friedhelm Hildebrandt; Aysin Bakkaloglu; Chou-Long Huang; Massimo Attanasio
Journal:  J Am Soc Nephrol       Date:  2012-12-28       Impact factor: 14.978

  7 in total
  2 in total

1.  Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications.

Authors:  Maria Izabel de Holanda; Caio Perez Gomes; Stanley de Almeida Araujo; David Campos Wanderley; Renato George Eick; Gustavo Coelho Dantas; Michele Karen Dos Santos Tino; João Bosco Pesquero; Lilian Monteiro Pereira Palma
Journal:  Clin Kidney J       Date:  2019-05-14

2.  Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey.

Authors:  Sarah Wente-Schulz; Marina Aksenova; Atif Awan; Cahyani Gita Ambarsari; Francesca Becherucci; Francesco Emma; Marc Fila; Telma Francisco; Ibrahim Gokce; Bora Gülhan; Matthias Hansen; Timo Jahnukainen; Mahmoud Kallash; Konstantinos Kamperis; Sherene Mason; Antonio Mastrangelo; Francesca Mencarelli; Bogna Niwinska-Faryna; Michael Riordan; Rina R Rus; Seha Saygili; Erkin Serdaroglu; Sevgin Taner; Rezan Topaloglu; Enrico Vidal; Robert Woroniecki; Sibel Yel; Jakub Zieg; Lars Pape
Journal:  BMJ Open       Date:  2021-05-28       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.